Paper Details 
Original Abstract of the Article :
T helper type 2 (Th2) and regulatory T cells (T(reg) ) have been postulated to have critical roles in the pathogenesis of allergic asthma. Cytotoxic T lymphocyte antigen 4 immunoglobulin (CTLA4Ig) gene-modified dendritic cells (DC-CTLA4Ig) have the potential to reduce Th2 cells and induce T(reg) cel...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110329/

データ提供:米国国立医学図書館(NLM)

Asthma: Finding Balance in the Desert of Inflammation

Asthma is a chronic inflammatory disease of the airways, characterized by wheezing, coughing, and shortness of breath. This research explores the potential of cytotoxic T lymphocyte antigen 4 immunoglobulin (CTLA4Ig) gene-modified dendritic cells (DC-CTLA4Ig) to modulate the immune response in asthma. The study investigates the therapeutic effects of DC-CTLA4Ig in a murine model of asthma, examining its ability to reduce airway inflammation and hyperresponsiveness.

A New Oasis for Asthma: Modulating the Immune Response

The study reveals that DC-CTLA4Ig treatment effectively reduces airway hyperresponsiveness, alleviates airway inflammation, and alters the balance of T helper cell subsets in the lungs. This suggests that DC-CTLA4Ig could be a promising new therapeutic approach for asthma, offering a way to modulate the immune system and restore balance in the airways. It's like finding a hidden oasis in the desert of asthma, where the immune system is gently guided back to a state of equilibrium.

Hope for Asthma Patients: Finding Balance in the Desert

This research provides a beacon of hope for patients suffering from asthma. It's like discovering a new oasis in the desert of inflammation, offering a potential path to better control and management of the disease. The study underscores the importance of exploring innovative approaches to modulate the immune response and to develop targeted therapies that address the underlying causes of asthma.

Dr. Camel's Conclusion

This research provides a compelling case for the therapeutic potential of DC-CTLA4Ig in the treatment of asthma. It's like finding a new oasis in the vast desert of asthma research, offering a glimmer of hope for patients seeking more effective treatments. The study inspires further exploration of the role of immune modulation in managing asthma and the development of personalized therapies that cater to individual needs.

Date :
  1. Date Completed 2011-08-29
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

21545583

DOI: Digital Object Identifier

PMC3110329

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.